Serum levels of TNF-alpha in patients with chronic schizophrenia during treatment augmentation with sarcosine (results of the PULSAR study)

First and second generation antipsychotic drugs still constitute the unquestioned first-choice therapy of schizophrenia, but this treatment has its limited efficacy against the broad spectrum of symptoms. Antipsychotics control positive symptoms (delusions, hallucinations, thought disorders, bizarre behavior) relatively well, but the primary negative, cognitive and affective dimensions remain rather resistant. Compounds with glutamatergic, cholinergic or serotonergic properties are currently under investigation as new treatment options, mostly for augmenting complementing and enhancing the effects of antipsychotics (Ellaithy et al., 2015; Garay et al., 2016; Hashimoto, 2014; McCreary and Newman-Tancredi, 2015; McLean et al., 2016; Wallace and Bertrand, 2015).
Source: Psychiatry Research - Category: Psychiatry Authors: Source Type: research